SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system

BACKGROUND: Sodium glucose cotransporter-2 inhibitors (SGLT2i) reduce the risk of heart failure and new data show they can prevent atrial fibrillation (AF). We examined the association between SGLT2i and AF in the Food and Drug Administration adverse event reporting system (FAERS). METHODS: We mined...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonora, Benedetta Maria, Raschi, Emanuel, Avogaro, Angelo, Fadini, Gian Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879696/
https://www.ncbi.nlm.nih.gov/pubmed/33573667
http://dx.doi.org/10.1186/s12933-021-01243-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879696/
https://www.ncbi.nlm.nih.gov/pubmed/33573667
http://dx.doi.org/10.1186/s12933-021-01243-4

Ejemplares similares